Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the recommended dose, safety, pharmacokinetics, and early
efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or
refractory CTCL.